Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 11/20 | 0.46 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513999 | 0.88 | KDR (0.48) | KDRHTR6SLC9A3HTR1ASLC6A2 | |
| SCHEMBL20129648 | 0.85 | KDR (0.48) | KDRHTR6HTR1ASLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL20141168 | 0.84 | KDR (0.47) | KDRHTR6HTR1ASLC6A2SLC6A4 | |
| SCHEMBL22542102 | 0.83 | ALDH1A1 (0.54) | HTR6HTR1ASLC6A4HTR7HTR3A | |
| SCHEMBL2557226 | 0.82 | USP2 (0.54) | HTR6SLC9A3HTR1ASLC6A4HTR7 | |
| SCHEMBL4420344 | 0.80 | HTR6 (0.46) | HTR6HTR7HTR3A | |
| SCHEMBL24451858 | 0.79 | HTR6 (0.46) | HTR6HTR1AHTR3A | |
| SCHEMBL20884583 | 0.79 | HTR6 (0.43) | HTR6SLC6A2HTR3A | |
| SCHEMBL8575378 | 0.78 | SLC9A1 (0.52) | HTR6 | |
| SCHEMBL3848435 | 0.78 | HTR6 (0.67) | HTR6HTR1ASLC6A2HTR7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722661-B2 | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase | HOFFMANN-LA ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130345215-A1 | PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-26 | — | — | US | disclosed |
| US-20130331375-A1 | PYRROLOPYRIMIDONE AND PYRROLOPYRIDONE INHIBITORS OF TANKYRASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-12 | — | — | US | disclosed |
| WO-2013066729-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130012485-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA (FR) | 2012-02-16 | — | — | US | disclosed |
| CN-102295636-A | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | — | 2011-12-28 | — | — | CN | disclosed |
| EP-2392571-A2 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | BISSANTZ CATERINA | 2010-09-02 | — | — | US | disclosed |
| US-7781436-B2 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101610761-A | 1-amino methyl-L-phenyl-cyclohexane-derivant as the DDP-IV inhibitor | NOVARTIS AG (CH) | 2009-12-23 | — | — | CN | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| CN-101400653-A | 11-beta HSD1 inhibitors | WYETH CORP (US) | 2009-04-01 | — | — | CN | disclosed |
| CN-101277945-A | Indol-3-yl-carbonyl-piperidine and piperazine derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-01 | — | — | CN | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| EP-1917255-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007014851-A2 | INDOL-3-YL-CARBONYL-PIPERIDIN AND PIPERAZIN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222357-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | KDR 1005/4885HTR6 117/4885SLC9A3 2780/4885 |
| US-20120040990-A1 | INDOL-3-Y-CARBONYL-PIPERIDIN AND PIPERAZIN-DERIVATIVES | AVPR1A, AVPR2, OXTR | KDR 1005/4885HTR6 117/4885SLC9A3 2780/4885 |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | AVPR1A, AVPR2, OXTR | KDR 1005/4885HTR6 117/4885SLC9A3 2780/4885 |
| US-20130012485-A1 | ORGANIC COMPOUNDS | DPP4, DPP3, DPP7 | KDR 2285/4885HTR6 896/4885SLC9A3 1208/4885 |
| US-20130345215-A1 | PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE | TNKS1BP1, TPI1, TNKS | KDR 1081/4885HTR6 4215/4885SLC9A3 2821/4885 |
| US-20130331375-A1 | PYRROLOPYRIMIDONE AND PYRROLOPYRIDONE INHIBITORS OF TANKYRASE | TNKS1BP1, TNKS, TPI1 | KDR 1069/4885HTR6 4447/4885SLC9A3 4538/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | KDR 4762/4885HTR6 1213/4885SLC9A3 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.